Asparaginase toxicity in Hispanic adult and pediatric patients with acute lymphoblastic leukemia: current understanding

References

• Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J. 2017 Jun 30;7(6):e577. doi: 10.1038/bcj.2017.53
   PubMedGoogle Scholar
• Kantarjian HM, Keating MJ, Freireich EJ. Toward the potential cure of leukemias in the next decade. Cancer. 2018 Nov 15;124(22):4301–4313. doi: 10.1002/cncr.31669
   PubMed Web of Science ®Google Scholar
• Iacobucci I, Mullighan CG. Genetic basis of acute lymphoblastic leukemia. J Clin Oncol. 2017 Mar 20;35(9):975–983. doi: 10.1200/JCO.2016.70.7836
   PubMed Web of Science ®Google Scholar
• Jabbour E, O’Brien S, Konopleva M, et al. New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia. Cancer. 2015 Aug 1;121(15):2517–2528. doi: 10.1002/cncr.29383
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin. 2022 Jan;72(1):7–33.
   PubMed Web of Science ®Google Scholar
• Aldoss I, Stein AS. Advances in adult acute lymphoblastic leukemia therapy. Leuk Lymphoma. 2018 May;59(5):1033–1050. doi: 10.1080/10428194.2017.1354372
   PubMed Web of Science ®Google Scholar
• Douer D, Aldoss I, Lunning MA, et al. Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia. J Clin Oncol. 2014 Mar 20;32(9):905–911. doi: 10.1200/JCO.2013.50.2708
   PubMed Web of Science ®Google Scholar
• Stock W, Luger SM, Advani AS, et al. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood. 2019 Apr 4;133(14):1548–1559. doi: 10.1182/blood-2018-10-881961
   PubMed Web of Science ®Google Scholar
• Wetzler M, Sanford BL, Kurtzberg J, et al. Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511. Blood. 2007 May 15;109(10):4164–4167. doi: 10.1182/blood-2006-09-045351
   PubMed Web of Science ®Google Scholar
• Roberts KG, Gu Z, Payne-Turner D, et al. High frequency and poor outcome of Philadelphia chromosome-like acute lymphoblastic leukemia in adults. J Clin Oncol. 2017 Feb;35(4):394–401.
   PubMed Web of Science ®Google Scholar
• Sive JI, Buck G, Fielding A, et al. Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial. Br J Haematol. 2012 May;157(4):463–471.
   PubMed Web of Science ®Google Scholar
• Samra B, Jabbour E, Ravandi F, et al. Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions. J Hematol Oncol. 2020 Jun 5;13(1):70. doi: 10.1186/s13045-020-00905-2
   PubMed Web of Science ®Google Scholar
• Barrington-Trimis JL, Cockburn M, Metayer C, et al. Rising rates of acute lymphoblastic leukemia in Hispanic children: trends in incidence from 1992 to 2011. Blood. 2015 May 7;125(19):3033–3034. doi: 10.1182/blood-2015-03-634006
   PubMed Web of Science ®Google Scholar
• Shoag JM, Barredo JC, Lossos IS, et al. Acute lymphoblastic leukemia mortality in Hispanic Americans. Leuk Lymphoma. 2020 Nov;61(11):2674–2681.
   PubMed Web of Science ®Google Scholar
• Pullarkat ST, Danley K, Bernstein L, et al. High lifetime incidence of adult acute lymphoblastic leukemia among Hispanics in California. Cancer Epidemiol Biomarkers Prev. 2009 Feb;18(2):611–615.
   PubMed Web of Science ®Google Scholar
• Gupta S, Wang C, Raetz EA, et al. Impact of asparaginase discontinuation on outcome in childhood acute lymphoblastic leukemia: a report from the children’s oncology group. J Clin Oncol. 2020 Jun 10;38(17):1897–1905. doi: 10.1200/JCO.19.03024
   PubMed Web of Science ®Google Scholar
• Aldoss I, Yin J, Wall A, et al. The impact of early PEG-asparaginase discontinuation in young adults with ALL: a post hoc analysis of the CALGB 10403 study. Blood Adv. 2023 Jan 24;7(2):196–204. doi: 10.1182/bloodadvances.2022007791
   PubMed Web of Science ®Google Scholar
• Batool T, Makky EA, Jalal M, et al. A comprehensive review on L-Asparaginase and Its Applications. Appl Biochem Biotechnol. 2016 Mar;178(5):900–923.
   PubMed Web of Science ®Google Scholar
• Asselin B, Rizzari C. Asparaginase pharmacokinetics and implications of therapeutic drug monitoring. Leuk Lymphoma. 2015;56(8):2273–2280. doi: 10.3109/10428194.2014.1003056
   PubMed Web of Science ®Google Scholar
• Shrivastava A, Khan AA, Khurshid M, et al. Recent developments in L-asparaginase discovery and its potential as anticancer agent. Crit Rev Oncol Hematol. 2016 Apr;100:1–10.
   PubMed Web of Science ®Google Scholar
• Avramis VI, Panosyan EH, Avramis VI. Pharmacokinetic/Pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future. Clin Pharmacokinet. 2005;44(4):367–393. doi: 10.2165/00003088-200544040-00003
   PubMed Web of Science ®Google Scholar
• Lomelino CL, Andring JT, McKenna R, et al. Asparagine synthetase: Function, structure, and role in disease. J Biol Chem. 2017 Dec 8;292(49):19952–19958. doi: 10.1074/jbc.R117.819060
   PubMed Web of Science ®Google Scholar
• Chan WK, Horvath TD, Tan L, et al. Glutaminase activity of L-asparaginase contributes to durable preclinical activity against acute lymphoblastic leukemia. Mol Cancer Ther. 2019 Sep;18(9):1587–1592.
   PubMed Web of Science ®Google Scholar
• Fonseca MHG, Fiuza TDS, Morais SB, et al. Circumventing the side effects of L-asparaginase. Biomed Pharmacother. 2021 Jul;139:111616.
   PubMed Web of Science ®Google Scholar
• Salzer W, Bostrom B, Messinger Y, et al. Asparaginase activity levels and monitoring in patients with acute lymphoblastic leukemia. Leuk Lymphoma. 2018 Aug;59(8):1797–1806.
   PubMed Web of Science ®Google Scholar
• Maese LD, Loh ML, Choi MR, et al. Efficacy, safety, and population pharmacokinetic modeling of intravenous recombinant erwinia asparaginase (JZP458) in acute lymphoblastic leukemia/lymphoblastic lymphoma: results from study AALL1931. Blood. 2022 Sep 15;140(Supplement 1):8969–8970. doi: 10.1182/blood-2022-160192
   Google Scholar
• Dinndorf PA, Gootenberg J, Cohen MH, et al. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). Oncology. 2007 Aug;12(8):991–998.
   Google Scholar
• Thu Huynh V, Bergeron S. Asparaginase toxicities: identification and management in patients with acute lymphoblastic leukemia. Clin J Oncol Nurs. 2017 Oct 1;21(5):E248–E259. doi: 10.1188/17.CJON.E248-E259
   PubMed Web of Science ®Google Scholar
• Modi T, Gervais D. Improved pharmacokinetic and pharmacodynamic profile of a novel PEGylated native Erwinia chrysanthemi L-Asparaginase. Invest New Drugs. 2022 Feb;40(1):21–29. doi: 10.1007/s10637-021-01173-8
   PubMed Web of Science ®Google Scholar
• Angiolillo AL, Schore RJ, Devidas M, et al. Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from children’s oncology group study AALL07P4. J Clin Oncol. 2014 Dec 1;32(34):3874–3882. doi: 10.1200/JCO.2014.55.5763
   PubMed Web of Science ®Google Scholar
• Narta UK, Kanwar SS, Azmi W. Pharmacological and clinical evaluation of L-asparaginase in the treatment of leukemia. Crit Rev Oncol Hematol. 2007 Mar;61(3):208–221. doi: 10.1016/j.critrevonc.2006.07.009
   PubMed Web of Science ®Google Scholar
• Juluri KR, Siu C, Cassaday RD. Asparaginase in the treatment of acute lymphoblastic leukemia in adults: current evidence and place in therapy. Blood Lymphat Cancer. 2022;12:55–79. doi: 10.2147/BLCTT.S342052
   PubMed Web of Science ®Google Scholar
• Pieters R, Hunger SP, Boos J, et al. L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer. 2011 Jan 15;117(2):238–249. doi: 10.1002/cncr.25489
   PubMed Web of Science ®Google Scholar
• Amylon MD, Shuster J, Pullen J, et al. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. Leukemia. 1999 Mar;13(3):335–342.
   PubMed Web of Science ®Google Scholar
• Avramis VI, Sencer S, Periclou AP, et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a children’s cancer group study. Blood. 2002 Mar 15;99(6):1986–1994. doi: 10.1182/blood.V99.6.1986
   PubMed Web of Science ®Google Scholar
• Kahn JM, Cole PD, Blonquist TM, et al. An investigation of toxicities and survival in Hispanic children and adolescents with ALL: Results from the Dana-Farber cancer institute all consortium protocol 05-001. Pediatr Blood Cancer. 2018 Mar;65(3):e26871. doi: 10.1002/pbc.26871
   Web of Science ®Google Scholar
• Kahn JM, Keegan TH, Tao L, et al. Racial disparities in the survival of American children, adolescents, and young adults with acute lymphoblastic leukemia, acute myelogenous leukemia, and Hodgkin lymphoma. Cancer. 2016 Sep 1;122(17):2723–2730. doi: 10.1002/cncr.30089
   PubMed Web of Science ®Google Scholar
• Maese L, Rau RE. Current use of asparaginase in acute lymphoblastic leukemia/lymphoblastic lymphoma. Front Pediatr. 2022;10:902117. doi: 10.3389/fped.2022.902117
   PubMed Web of Science ®Google Scholar
• Storring JM, Minden MD, Kao S, et al. Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen. Br J Haematol. 2009 Jun;146(1):76–85.
   PubMed Web of Science ®Google Scholar
• Douer D, Gokbuget N, Stock W, et al. Optimizing use of L-asparaginase-based treatment of adults with acute lymphoblastic leukemia. Blood Rev. 2022 May;53:100908.
   PubMed Web of Science ®Google Scholar
• Larsen EC, Devidas M, Chen S, et al. Dexamethasone and high-dose methotrexate improve outcome for children and young adults with high-risk B-acute lymphoblastic leukemia: a report from children’s oncology group study AALL0232. J Clin Oncol. 2016 Jul 10;34(20):2380–2388. doi: 10.1200/JCO.2015.62.4544
   PubMed Web of Science ®Google Scholar
• Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber consortium protocol 91-01. Blood. 2001 Mar 1;97(5):1211–1218. doi: 10.1182/blood.V97.5.1211
   PubMed Web of Science ®Google Scholar
• Burke MJ, Zalewska-Szewczyk B. Hypersensitivity reactions to asparaginase therapy in acute lymphoblastic leukemia: immunology and clinical consequences. Future Oncol. 2022 Mar;18(10):1285–1299. doi: 10.2217/fon-2021-1288
   PubMed Web of Science ®Google Scholar
• Burke PW, Hoelzer D, Park JH, et al. Managing toxicities with asparaginase-based therapies in adult ALL: summary of an ESMO open-cancer horizons roundtable discussion. ESMO Open. 2020 Oct;5(5):e000858.
   PubMed Web of Science ®Google Scholar
• Aldoss I, Pourhassan H, Douer D. SOHO state of the art updates and next questions | asparaginase-understanding and overcoming toxicities in adults with ALL. Clin Lymphoma Myeloma Leuk. 2022 Nov;22(11):787–794. doi: 10.1016/j.clml.2022.08.009
   PubMedGoogle Scholar
• Burke MJ, Rheingold SR. Differentiating hypersensitivity versus infusion-related reactions in pediatric patients receiving intravenous asparaginase therapy for acute lymphoblastic leukemia. Leuk Lymphoma. 2017 Mar;58(3):540–551. doi: 10.1080/10428194.2016.1213826
   PubMed Web of Science ®Google Scholar
• Dharia P, Swartz MD, Bernhardt MB, et al. Clinical and demographic factors contributing to asparaginase-associated toxicities in children with acute lymphoblastic leukemia. Leuk Lymphoma. 2022 Dec;63(12):2948–2954.
   PubMed Web of Science ®Google Scholar
• Fernandez CA, Smith C, Yang W, et al. Genome-wide analysis links NFATC2 with asparaginase hypersensitivity. Blood. 2015 Jul 2;126(1):69–75. doi: 10.1182/blood-2015-02-628800
   PubMed Web of Science ®Google Scholar
• Hojfeldt SG, Wolthers BO, Tulstrup M, et al. Genetic predisposition to PEG-asparaginase hypersensitivity in children treated according to NOPHO ALL2008. Br J Haematol. 2019 Feb;184(3):405–417.
   PubMed Web of Science ®Google Scholar
• Maese L, Loh ML, Choi MR, et al. Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia: results from the phase 2/3 AALL1931 study. Blood. 2023 Feb 16;141(7):704–712. doi: 10.1182/blood.2022016923
   PubMed Web of Science ®Google Scholar
• Wu S, Wang M, Alqahtani A, et al. Hispanic ethnicity and the rs4880 variant in SOD2 are associated with elevated liver enzymes and bilirubin levels in children receiving asparaginase-containing chemotherapy for acute lymphoblastic leukemia. Biomed Pharmacother. 2022 Jun;150:113000. doi: 10.1016/j.biopha.2022.113000
   PubMed Web of Science ®Google Scholar
• Hashmi SK, Navai SA, Chambers TM, et al. Incidence and predictors of treatment-related conjugated hyperbilirubinemia during early treatment phases for children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2020 Feb;67(2):e28063.
   PubMed Web of Science ®Google Scholar
• Yang W, Karol SE, Hoshitsuki K, et al. Association of inherited genetic factors with drug-induced hepatic damage among children with acute lymphoblastic leukemia. JAMA Netw Open. 2022 Dec 1;5(12):e2248803. doi: 10.1001/jamanetworkopen.2022.48803
   PubMed Web of Science ®Google Scholar
• Junk SV, Schaeffeler E, Zimmermann M, et al. Chemotherapy-related hyperbilirubinemia in pediatric acute lymphoblastic leukemia: a genome-wide association study from the AIEOP-BFM ALL study group. J Exp Clin Cancer Res. 2023 Jan 13;42(1):21. doi: 10.1186/s13046-022-02585-x
   PubMed Web of Science ®Google Scholar
• Liu Y, Fernandez CA, Smith C, et al. Genome-wide study links PNPLA3 variant with elevated hepatic transaminase after acute lymphoblastic leukemia therapy. Clin Pharmacol Ther. 2017 Jul;102(1):131–140.
   PubMed Web of Science ®Google Scholar
• Alachkar H, Fulton N, Sanford B, et al. Expression and polymorphism (rs4880) of mitochondrial superoxide dismutase (SOD2) and asparaginase induced hepatotoxicity in adult patients with acute lymphoblastic leukemia. Pharmacogenomics J. 2017 Jun;17(3):274–279.
   PubMed Web of Science ®Google Scholar
• Abdelmeseeh E, Dragon M, Tomassetti S. Evaluating asparaginase toxicity in Hispanic patients with acute lymphoblastic leukemia in a large safety-net hospital. J Clin Oncol. 2022;40(16_suppl):e19012–e19012. doi: 10.1200/JCO.2022.40.16_suppl.e19012
   Web of Science ®Google Scholar
• Yi JS, Chambers TM, Getz KD, et al. A report from the leukemia electronic abstraction of records network on risk of hepatotoxicity during pediatric acute lymphoblastic leukemia treatment. Haematologica. 2022 May 1;107(5):1185–1188. doi: 10.3324/haematol.2021.279805
   PubMed Web of Science ®Google Scholar
• Burke PW, Aldoss I, Lunning MA, et al. Pegaspargase-related high-grade hepatotoxicity in a pediatric-inspired adult acute lymphoblastic leukemia regimen does not predict recurrent hepatotoxicity with subsequent doses. Leuk Res. 2018 Mar;66:49–56.
   PubMed Web of Science ®Google Scholar
• Patel B, Kirkwood AA, Dey A, et al. Pegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: toxicity data from the UKALL14 trial. Leukemia. 2017 Jan;31(1):58–64.
   PubMed Web of Science ®Google Scholar
• Gokbuget N, Stanze D, Beck J, et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood. 2012 Sep 6;120(10):2032–2041. doi: 10.1182/blood-2011-12-399287
   PubMed Web of Science ®Google Scholar
• Aldoss I, Douer D. How I treat the toxicities of pegasparaginase in adults with acute lymphoblastic leukemia. Blood. 2020 Mar 26;135(13):987–995. doi: 10.1182/blood.2019002132
   PubMed Web of Science ®Google Scholar
• Alshiekh-Nasany R, Douer D. L-Carnitine for treatment of pegasparaginase-induced hepatotoxicity. Acta Haematol. 2016;135(4):208–210. doi: 10.1159/000442342
   PubMed Web of Science ®Google Scholar
• Lee C, Leventhal TM, Anugwom CM. L-Asparaginase-induced hepatotoxicity treated successfully with L-Carnitine and Vitamin B Infusion. Cureus. 2021 Aug;13(8):e16917.
   PubMed Web of Science ®Google Scholar
• Defina M, Lazzarotto D, Guolo F, et al. Levocarnitine supplementation for asparaginase-induced hepatotoxicity in adult acute lymphoblastic leukemia patients: A multicenter observational study of the campus all group. Leuk Res. 2022 Nov;122:106963.
   PubMed Web of Science ®Google Scholar
• Trang E, Ngo D, Chen J, et al. Levocarnitine for pegasparaginase-induced hepatotoxicity in acute lymphoblastic leukemia. Leuk Lymphoma. 2020 Dec;61(13):3161–3164.
   PubMed Web of Science ®Google Scholar
• Schulte R, Hinson A, Huynh V, et al. Levocarnitine for pegaspargase-induced hepatotoxicity in older children and young adults with acute lymphoblastic leukemia. Cancer Med. 2021 Nov;10(21):7551–7560.
   PubMed Web of Science ®Google Scholar
• Rytting ME, Thomas DA, O’Brien SM, et al. Augmented Berlin-Frankfurt-Munster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). Cancer. 2014 Dec 1;120(23):3660–3668. doi: 10.1002/cncr.28930
   PubMed Web of Science ®Google Scholar
• Grimes AC, Chen Y, Bansal H, et al. Genetic markers for treatment-related pancreatitis in a cohort of Hispanic children with acute lymphoblastic leukemia. Support Care Cancer. 2021 Feb;29(2):725–731.
   PubMed Web of Science ®Google Scholar
• Liu C, Yang W, Devidas M, et al. Clinical and genetic risk factors for acute pancreatitis in patients with acute lymphoblastic leukemia. J Clin Oncol. 2016 Jun 20;34(18):2133–2140. doi: 10.1200/JCO.2015.64.5812
   PubMed Web of Science ®Google Scholar
• Lee BJ, Doh J, Chan A, et al. Increased incidence of Pegaspargase-induced hypertriglyceridemia and associated pancreatitis observed in the Hispanic adult patient population. Leuk Lymphoma. 2022 Dec;63(12):2992–2995. doi: 10.1080/10428194.2022.2098288
   PubMed Web of Science ®Google Scholar
• Schmiegelow K, Attarbaschi A, Barzilai S, et al. Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus. Lancet Oncol. 2016 Jun;17(6):e231–e239.
   PubMed Web of Science ®Google Scholar
• Wolthers BO, Frandsen TL, Baruchel A, et al. Asparaginase-associated pancreatitis in childhood acute lymphoblastic leukaemia: an observational Ponte di Legno Toxicity Working Group study. Lancet Oncol. 2017 Sep;18(9):1238–1248.
   PubMed Web of Science ®Google Scholar
• Kearney SL, Dahlberg SE, Levy DE, et al. Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis. Pediatr Blood Cancer. 2009 Aug;53(2):162–167.
   PubMed Web of Science ®Google Scholar
• Plourde PV, Jeha S, Hijiya N, et al. Safety profile of asparaginase Erwinia chrysanthemi in a large compassionate-use trial. Pediatr Blood Cancer. 2014 Jul;61(7):1232–1238.
   PubMed Web of Science ®Google Scholar
• DeAngelo DJ, Stevenson KE, Dahlberg SE, et al. Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia. Leukemia. 2015 Mar;29(3):526–534.
   PubMed Web of Science ®Google Scholar
• Grace RF, Dahlberg SE, Neuberg D, et al. The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. Br J Haematol. 2011 Feb;152(4):452–459.
   PubMed Web of Science ®Google Scholar
• Rank CU, Toft N, Tuckuviene R, et al. Thromboembolism in acute lymphoblastic leukemia: results of NOPHO ALL2008 protocol treatment in patients aged 1 to 45 years. Blood. 2018 May 31;131(22):2475–2484. doi: 10.1182/blood-2018-01-827949
   PubMed Web of Science ®Google Scholar
• Greiner J, Schrappe M, Claviez A, et al. THROMBOTECT - a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents. Haematologica. 2019 Apr;104(4):756–765.
   PubMed Web of Science ®Google Scholar
• Stock W, Douer D, DeAngelo DJ, et al. Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. Leuk Lymphoma. 2011 Dec;52(12):2237–2253.
   PubMed Web of Science ®Google Scholar
• Aldoss I, Douer D, Behrendt CE, et al. Toxicity profile of repeated doses of PEG-asparaginase incorporated into a pediatric-type regimen for adult acute lymphoblastic leukemia. Eur J Haematol. 2016 Apr;96(4):375–380.
   PubMed Web of Science ®Google Scholar
• Duarte X, Esteves S, Neto AM, et al. Incidence and risk factors for central nervous system thrombosis in paediatric acute lymphoblastic leukaemia during intensive asparaginase treatment: a single-centre cohort study. Br J Haematol. 2016 Jul;174(2):280–291.
   PubMed Web of Science ®Google Scholar
• Couturier MA, Huguet F, Chevallier P, et al. Cerebral venous thrombosis in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma during induction chemotherapy with l-asparaginase: The GRAALL experience. Am J Hematol. 2015 Nov;90(11):986–991.
   PubMed Web of Science ®Google Scholar
• Yang W, Kovacic JC, Cromwell C, et al. Myocardial infarction in a young man receiving chemotherapy for acute lymphoblastic leukemia. Clin Adv Hematol Oncol. 2013 Oct;11(10):672–675.
   PubMedGoogle Scholar
• Schmiegelow K, Rank CU, Stock W, et al. SOHO state of the art updates and next questions: management of asparaginase toxicity in adolescents and young adults with acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2021 Nov;21(11):725–733.
   PubMed Web of Science ®Google Scholar
• Daley RJ, Rajeeve S, Kabel CC, et al. Pegaspargase can safely be administered in adults age 40 and older with acute lymphoblastic leukemia. Blood. 2019;134(Supplement_1):3816–3816. doi: 10.1182/blood-2019-124727
   Google Scholar
• Mogensen SS, Schmiegelow K, Grell K, et al. Hyperlipidemia is a risk factor for osteonecrosis in children and young adults with acute lymphoblastic leukemia. Haematologica. 2017 May;102(5):e175–e178.
   PubMed Web of Science ®Google Scholar
• Howard SC, Pui CH. Endocrine complications in pediatric patients with acute lymphoblastic leukemia. Blood Rev. 2002 Dec;16(4):225–243. doi: 10.1016/S0268-960X(02)00042-5
   PubMed Web of Science ®Google Scholar
• Pui CH, Burghen GA, Bowman WP, et al. Risk factors for hyperglycemia in children with leukemia receiving L-asparaginase and prednisone. J Pediatr. 1981 Jul;99(1):46–50.
   PubMed Web of Science ®Google Scholar
• Baillargeon J, Langevin AM, Mullins J, et al. Transient hyperglycemia in Hispanic children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2005 Dec;45(7):960–963.
   PubMed Web of Science ®Google Scholar
• Savage B, Cole PD, Lin H. Racial and economic differences in the risk of hyperglycemia in children hospitalized with acute lymphoblastic leukemia. J Pediatr Oncol Nurs. 2021 Sep;38(5):277–284. doi: 10.1177/10434542211011040
   PubMed Web of Science ®Google Scholar
• Aisyi M, Andriastuti M, Kurniati N. The effect of combination of steroid and L-asparaginase on hyperglycemia in children with acute lymphoblastic leukemia (ALL). Asian Pac J Cancer Prev. 2019 Sep 1;20(9):2619–2624. doi: 10.31557/APJCP.2019.20.9.2619
   PubMedGoogle Scholar
• McNeil DE, Cote TR, Clegg L, et al. SEER update of incidence and trends in pediatric malignancies: acute lymphoblastic leukemia. Med Pediatr Oncol. 2002 Dec;39(6):554–557. discussion 552-3. doi: 10.1002/mpo.10161
   PubMedGoogle Scholar
• Sasaki K, Jabbour E, Short NJ, et al. Acute lymphoblastic leukemia: A population-based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1980-2017. Am J Hematol. 2021 Jun 1;96(6):650–658. doi: 10.1002/ajh.26156
   PubMed Web of Science ®Google Scholar
• Law JY, Dao BD, Le P, et al. Impact of body mass index and ethnicity on asparaginase toxicity in adult acute lymphoblastic leukemia patients. J Clin Oncol. 2015;33(15_suppl):e18051–e18051. doi: 10.1200/jco.2015.33.15_suppl.e18051
   Web of Science ®Google Scholar
• Howell CR, Juarez L, Agne AA, et al. Assessing hispanic/latino and non-hispanic white social determinants of obesity among a community sample of residents in the Rural Southeast US. J Immigr Minor Health. 2022 Dec;24(6):1469–1479.
   PubMed Web of Science ®Google Scholar
• Tsoi MF, Li HL, Feng Q, et al. Prevalence of childhood obesity in the United States in 1999-2018: A 20-year analysis. Obes Facts. 2022;15(4):560–569. doi: 10.1159/000524261
   PubMed Web of Science ®Google Scholar
• Butturini AM, Dorey FJ, Lange BJ, et al. Obesity and outcome in pediatric acute lymphoblastic leukemia. J Clin Oncol. 2007 May 20;25(15):2063–2069. doi: 10.1200/JCO.2006.07.7792
   PubMed Web of Science ®Google Scholar
• Christ TN, Stock W, Knoebel RW. Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen. J Oncol Pharm Pract. 2018 Jun;24(4):299–308. doi: 10.1177/1078155217701291
   PubMed Web of Science ®Google Scholar
• Zhang X, Heredia NI, Balakrishnan M, et al. Prevalence and factors associated with NAFLD detected by vibration controlled transient elastography among US adults: Results from NHANES 2017–2018. PLoS One. 2021;16(6):e0252164. doi: 10.1371/journal.pone.0252164
   PubMed Web of Science ®Google Scholar
• Kim D, Cholankeril G, Loomba R, et al. Prevalence of fatty liver disease and fibrosis detected by transient elastography in adults in the United States, 2017-2018. Clin Gastroenterol Hepatol. 2021 Jul;19(7):1499–1501 e2.
   PubMed Web of Science ®Google Scholar
• Diouf B, Wing C, Panetta JC, et al. Identification of small molecules that mitigate vincristine-induced neurotoxicity while sensitizing leukemia cells to vincristine. Clin Transl Sci. 2021 Jul;14(4):1490–1504.
   PubMed Web of Science ®Google Scholar
• Inaba H, Pui CH. Glucocorticoid use in acute lymphoblastic leukaemia. Lancet Oncol. 2010 Nov;11(11):1096–1106. doi: 10.1016/S1470-2045(10)70114-5
   PubMed Web of Science ®Google Scholar
• Yang FF, Xue TL, Gao C, et al. Effects of SLCO1B1 on elimination and toxicities of high-dose methotrexate in pediatric acute lymphoblastic leukemia. Pharmacogenomics. 2022 Oct;23(15):821–834.
   PubMed Web of Science ®Google Scholar
• Schafer ES, Bernhardt MB, Reichert KE, et al. Hispanic ethnicity as a risk factor for requiring glucarpidase rescue in pediatric patients receiving high-dose methotrexate. Am J Hematol. 2018 Feb;93(2):E40–E42.
   PubMed Web of Science ®Google Scholar
• Lennard L, Cartwright CS, Wade R, et al. Thiopurine methyltransferase and treatment outcome in the UK acute lymphoblastic leukaemia trial ALL2003. Br J Haematol. 2015 Aug;170(4):550–558.
   PubMed Web of Science ®Google Scholar
• Yang SK, Hong M, Baek J, et al. A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. Nat Genet. 2014 Sep;46(9):1017–1020.
   PubMed Web of Science ®Google Scholar
• Yang JJ, Landier W, Yang W, et al. Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia. J Clin Oncol. 2015 Apr 10;33(11):1235–1242. doi: 10.1200/JCO.2014.59.4671
   PubMed Web of Science ®Google Scholar
• Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature. 2015 Oct 15;526(7573):343–350. doi: 10.1038/nature15817
   PubMed Web of Science ®Google Scholar
• Lim JY, Bhatia S, Robison LL, et al. Genomics of racial and ethnic disparities in childhood acute lymphoblastic leukemia. Cancer. 2014 Apr 1;120(7):955–962. doi: 10.1002/cncr.28531
   PubMed Web of Science ®Google Scholar
• Mao X, Bigham AW, Mei R, et al. A genomewide admixture mapping panel for Hispanic/Latino populations. Am J Hum Genet. 2007 Jun;80(6):1171–1178. doi: 10.1086/518564
   PubMed Web of Science ®Google Scholar
• Martinez-Magana JJ, Genis-Mendoza AD, Villatoro Velazquez JA, et al. The identification of admixture patterns could refine pharmacogenetic counseling: analysis of a population-based sample in Mexico. Front Pharmacol. 2020;11:324. doi: 10.3389/fphar.2020.00324
   PubMed Web of Science ®Google Scholar
• Acharya S, Hsieh S, Shinohara ET, et al. Effects of race/ethnicity and socioeconomic status on outcome in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2016 Jul;38(5):350–354.
   PubMed Web of Science ®Google Scholar
• Dores GM, Devesa SS, Curtis RE, et al. Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. Blood. 2012 Jan 5;119(1):34–43. doi: 10.1182/blood-2011-04-347872
   PubMed Web of Science ®Google Scholar